PCSK9-LDLR Homogeneous Assay Kit
The PCSK9-LDLR Homogeneous Assay Kit is designed for screening and profiling purposes. Two pre-formulated assay buffers are supplied with this kit to validate PCSK9-LDLR binding affinity in either neutral or acidic binding conditions. With this kit, two simple steps are required for binding measurement. First, PCSK9 enzyme is incubated with LDLR in the preferred buffer for one hour. Next, donor and acceptor beads are added, followed by reading the Alpha-counts.
Figure 1: Illustration of the assay principle.
The FLAG-tag of LDLR binds to the anti-FLAG acceptor beads, while the His-tag on PCSK9 binds to Nickel Chelate donor beads, bringing the acceptor and donor beads in close proximity. Upon excitation of the donor bead a singlet oxygen is generated by the donor bead, which excites the acceptor bead and emits light proportionally to the level of interaction. AlphaLISA™ immunoassays are a no-wash alternative to ELISA immunoassays. These assays are robust, ideal for a minimal hands-on approach, and highly amenable to high-throughput applications.
Need us to run inhibitor screens or profile your compounds against PCSK9-LDLR? Check out our PCSK9 Screening Services.
- AlphaLISA® anti-FLAG acceptor beads, 5 mg/ml (PerkinElmer #AL112C)
- AlphaScreen® Nickel Chelate donor beads, 5 mg/ml (PerkinElmer #AS101D)
- Optiplate-384 (PerkinElmer #6007290)
Catalog # | Name | Amount | Storage |
71204 | PCSK9, His-Tag Recombinant* | 2 x 10 µg | -80°C |
71205 | LDLR, FLAG-Tag Recombinant* | 2 x 10 µg | -20°C |
33298 | 3x PL-01 Assay Buffer (pH 6) |
4 ml | -20°C |
79727 | 3x PL-02 Assay Buffer (pH 7.4) |
4 ml | -20°C |
* The concentration of protein is lot-specific and will be indicated on the tube containing the protein
PCSK9 (Proprotein convertase subtilisin/kexin type 9) functions as a negative regulator of hepatic low-density lipoprotein receptors (LDLRs) and therefore is a critical regulator of cholesterol metabolism. It is an endopeptidase that binds to the EGFR-like ectodomain of LDLR, leading to LDLR degradation, which in turn, results in increased circulating LDL. Inhibiting the PCSK9-LDLR interaction is an increasingly desirable therapeutic approach for lowering LDL-cholesterol levels to replace or supplement statins. New therapies are critical for addressing atherosclerosis, stroke, heart disease, and other cardiovascular disorders.